This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Cristofanilli M , Valero V , Mangalik A , Royce M , Rabinowitz I , Arena FP , Kroener JF , Curcio E , Watkins C , Bacus S , Cora EM , Anderson E , Magill PJ
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer
Clinical Cancer Research. 2010 Mar 15;16(6) :1904-14
PMID: 20215537 URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20215537
AbstractPURPOSE: This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC). EXPERIMENTAL DESIGN: Postmenopausal women with hormone receptor-positive measurable or evaluable MBC who had not received prior endocrine therapy for this disease stage or who developed metastatic disease during/after adjuvant tamoxifen were eligible. The primary response variable was progression-free survival (PFS) and secondary response variables included clinical benefit rate, objective response rate, overall survival, safety and tolerability, and pharmacokinetics. Tumor biomarker evaluation was an exploratory objective. RESULTS: Forty-three patients were randomized to anastrozole plus gefitinib and 50 patients were randomized to anastrozole plus placebo of a planned total of 174 patients (enrollment was prematurely discontinued due to slow recruitment). PFS for patients receiving the combination of anastrozole and gefitinib was longer than for patients receiving anastrozole plus placebo [hazard ratio (gefitinib/placebo), 0.55; 95% confidence interval, 0.32-0.94; median PFS, 14.7 versus 8.4 months]. The clinical benefit rate was 49% versus 34%, and the objective response rate was 2% versus 12% with anastrozole plus gefitinib and anastrozole plus placebo, respectively. No evidence of interaction between baseline biomarker levels and relative treatment effect was found. No unexpected adverse events were observed. CONCLUSION: This small randomized study showed that anastrozole in combination with gefitinib is associated with a marked advantage in PFS compared with anastrozole plus placebo, and that the combination was tolerated in postmenopausal women with hormone receptor-positive MBC. Further investigation of epidermal growth factor receptor inhibition in combination with endocrine therapy may be warranted.
NotesCristofanilli, Massimo Valero, Vicente Mangalik, Aroop Royce, Melanie Rabinowitz, Ian Arena, Francis P Kroener, Joan F Curcio, Elizabeth Watkins, Claire Bacus, Sarah Cora, Elsa M Anderson, Elizabeth Magill, Patrick J U54-CA 096297/CA/NCI NIH HHS/United States Clinical Trial, Phase II Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural United States Clinical cancer research : an official journal of the American Association for Cancer Research Clin Cancer Res. 2010 Mar 15;16(6):1904-14. Epub 2010 Mar 9.